Proposed LCD DL39297: Off-label Use of Rituximab and Rituximab Biosimilars — NGS
Policy LCD-DL39297 · Oncology
Impact of proposed LCD on Rituximab billing practices.
Code intelligence
C83.30 reimbursement alerts
Policy changes, MAC LCD updates, and CMS guidance matched to code C83.30.
Elevated code riskView ICD-10 detail
Signal breakdown
2 shown · 2 total in platform
Risk: Elevated
0
Critical
0%
1
High
50%
1
Routine
50%
0
Low
0%
New this month
—
alerts added in last 30 days
Effective soon
—
no upcoming deadlines
High
LCD L39297: Off-label Use of Rituximab and Rituximab Biosimilars — NGS
Policy LCD-L39297 · Oncology
Off-label Rituximab use may impact Medicare billing.
Audit documentation
Building an audit file that includes C83.30?
The Tripwire Audit Pack exports 12 months of Oncology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.
Get the Oncology audit pack — $349One-time purchase · not a subscription